Literature DB >> 19877115

Disparities in medical care among commercially insured patients with newly diagnosed breast cancer: opportunities for intervention.

Louise J Short1, Maxine D Fisher, Peter M Wahl, Monique B Kelly, Grant D Lawless, Sandra White, Nancy A Rodriguez, Vincent J Willey, Otis W Brawley.   

Abstract

BACKGROUND: African-American women have increased breast cancer mortality compared with white women. Diagnostic and treatment gaps may contribute to this disparity.
METHODS: In this retrospective, longitudinal cohort study, Southern US health plan claims data and linked medical charts were used to identify racial disparities in the diagnoses, treatment, and mortality of commercially insured women with newly diagnosed breast cancer. White women (n = 476) and African-American women (n = 99) with newly diagnosed breast cancer were identified by breast cancer claims codes (International Classification of Diseases, Ninth Revision, Clinical Modification codes 174, 233.0, 238.3, and 239.3) between January 2000 and December 2004. Race, diagnoses (breast cancer stage, estrogen/progesterone receptor [ER/PR]-positive status), treatment (breast-conserving surgery, antiestrogen therapy, and chemotherapy interruption or reduction), and all-cause mortality were assessed from medical charts. Multivariate regression analyses were adjusted for age, geography, and socioeconomic status to test the association of race with diagnoses/treatment.
RESULTS: White women were older (P < .001) and had higher rates of diagnosis at stage 0/I (55.2% vs 38.4%; P < .05) than African-American women. More white women had positive ER/PR status (75% vs 56% African-American; P = .001) and received antiestrogen therapy if they were positive (37.2% vs 27.3% African-American; P < .001). White women received slightly more breast-conserving surgery and chemotherapy dose modification than African-American women (P value nonsignificant). African-American women had a higher mortality rate (8.1%) than white women (3.6%; P = .06). In adjusted analyses, African-American women were diagnosed at later stages (odds ratio, 1.71; P = .02), and white women received more antiestrogen therapy (odds ratio, 2.1; P = .03).
CONCLUSIONS: Disparities in medical care among patients with newly diagnosed breast cancer were evident between African-American women and white women despite health plan insurance coverage. Interventions that address the gaps identified are needed. Copyright 2010 American Cancer Society.

Entities:  

Mesh:

Year:  2010        PMID: 19877115     DOI: 10.1002/cncr.24691

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  17 in total

Review 1.  Racial/Ethnic and socioeconomic disparities in endocrine therapy adherence in breast cancer: a systematic review.

Authors:  Megan C Roberts; Stephanie B Wheeler; Katherine Reeder-Hayes
Journal:  Am J Public Health       Date:  2015-04-23       Impact factor: 9.308

2.  Having health insurance does not eliminate race/ethnicity-associated delays in breast cancer diagnosis in the District of Columbia.

Authors:  Heather J Hoffman; Nancy L LaVerda; Paul H Levine; Heather A Young; Lisa M Alexander; Steven R Patierno
Journal:  Cancer       Date:  2011-02-24       Impact factor: 6.860

3.  Racial and ethnic differences in adjuvant hormonal therapy use.

Authors:  Jennifer C Livaudais; Christopher Li; Esther M John; Mary Beth Terry; Mary Daly; Saundra S Buys; Laurel Habel; Beti Thompson; N David Yanez; Gloria D Coronado
Journal:  J Womens Health (Larchmt)       Date:  2012-06-25       Impact factor: 2.681

4.  Racial variation in breast cancer treatment among Department of Defense beneficiaries.

Authors:  Lindsey Enewold; Jing Zhou; Katherine A McGlynn; William F Anderson; Craig D Shriver; John F Potter; Shelia H Zahm; Kangmin Zhu
Journal:  Cancer       Date:  2011-07-15       Impact factor: 6.860

5.  Racial/ethnic differences in initiation of adjuvant hormonal therapy among women with hormone receptor-positive breast cancer.

Authors:  Jennifer C Livaudais; Dawn L Hershman; Laurel Habel; Lawrence Kushi; Scarlett Lin Gomez; Christopher I Li; Alfred I Neugut; Louis Fehrenbacher; Beti Thompson; Gloria D Coronado
Journal:  Breast Cancer Res Treat       Date:  2011-09-16       Impact factor: 4.872

6.  Racial/ethnic differences in use and duration of adjuvant hormonal therapy for breast cancer in the women's health initiative.

Authors:  Jennifer C Livaudais; Andrea Lacroix; Rowan T Chlebowski; Christopher I Li; Laurel A Habel; Michael S Simon; Beti Thompson; Deborah O Erwin; F Allan Hubbell; Gloria D Coronado
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2012-12-28       Impact factor: 4.254

Review 7.  An eight-year snapshot of geospatial cancer research (2002-2009): clinico-epidemiological and methodological findings and trends.

Authors:  Dina N Kamel Boulos; Ramy R Ghali; Ezzeldin M Ibrahim; Maged N Kamel Boulos; Philip AbdelMalik
Journal:  Med Oncol       Date:  2010-06-30       Impact factor: 3.064

8.  Racial disparities in initiation of adjuvant endocrine therapy of early breast cancer.

Authors:  Katherine E Reeder-Hayes; Anne Marie Meyer; Stacie B Dusetzina; Huan Liu; Stephanie B Wheeler
Journal:  Breast Cancer Res Treat       Date:  2014-05-01       Impact factor: 4.872

9.  Early developments in gene-expression profiling of breast tumors: potential for increasing black-white patient disparities in breast cancer outcomes?

Authors:  Donna H Odierna; Aimee Afable-Munsuz; Ogechi Ikediobi; Mary Beattie; Sara Knight; Michelle Ko; Adrienne Wilson; Ninez A Ponce
Journal:  Per Med       Date:  2011-11       Impact factor: 2.512

10.  Racial/ethnic differences in breast cancer survival by inflammatory status and hormonal receptor status: an analysis of the Surveillance, Epidemiology, and End Results data.

Authors:  Jill K Schinkel; Shelia Hoar Zahm; Ismail Jatoi; Katherine A McGlynn; Christopher Gallagher; Catherine Schairer; Craig D Shriver; Kangmin Zhu
Journal:  Cancer Causes Control       Date:  2014-05-17       Impact factor: 2.506

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.